Bacillus strain LYM3 with antiviral function and application thereof

By providing the Bacillus strain CCTCCM2023870 and its metabolites combined with the vector, the side effects and poor efficacy of existing antiviral drugs have been solved, and efficient inhibition of influenza virus, herpes simplex virus and enterovirus has been achieved. Safety and efficiency.

CN119081907APending Publication Date: 2024-12-06INST PASTEUR OF SHANGHAI CHINESE ACADEMY OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310657117.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-05
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing antiviral drugs have problems of large side effects and difficult to satisfy the efficacy. It is urgent to develop new safe and effective biological strains with antiviral functions and their corresponding products.

Method used

Provide a Bacillus strain CCTCCM2023870 and its metabolites. By combining with pharmaceutical or food carriers, a composition is formed to prepare drugs or preparations for preventing and treating viral infections, including oral preparations, liquid preparations, etc., which contain safe and effective amount of Bacillus and/or its metabolites.

Benefits of technology

The Bacillus strain and its metabolites significantly inhibit the infection of influenza virus, herpes simplex virus and enterovirus, and is safe and efficient. It can effectively inhibit viral infection in vitro and in vivo, and its functional components are a kind of High temperature sensitive small molecule substances, non-protein.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides a bacillus strain with an antiviral function and application thereof. A novel bacillus strain LYM3 is separated and identified by the inventor, and experiments prove that the strain has an antiviral function.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to biomedicine and microbiology, in particular to a bacillus strain with antiviral function and application thereof. Background Art

[0002] Viruses can cause many different diseases. For example, influenza viruses can cause symptoms such as colds and fever; herpes simplex virus (HSV) can cause diseases such as gingivostomatitis, keratoconjunctivitis, encephalitis, and reproductive system infections; and enteroviruses can cause symptoms such as intestinal infections and diarrhea.

[0003] In order to deal with viruses, some antiviral drugs have been developed. However, most antiviral drugs have disadvantages such as large side effects and unsatisfactory efficacy.

[0004] Therefore, there is an urgent need in the art to develop new, safe and effective biological strains with antiviral functions and their corresponding products. Summary of the invention

[0005] The purpose of the present invention is to provide a safe and effective biological strain with antiviral function and its application.

[0006] The first aspect of the present invention provides a Bacillus, the deposit number of which is CCTCCM2023870.

[0007] In another preferred embodiment, the sequence of the 16s rDNA of Bacillus is selected from: SEQ ID NO.: 1, 2, 3, 4, 5, 6, 7, 8, or a combination thereof.

[0008] The second aspect of the present invention provides a composition comprising: (a) a safe and effective amount of the Bacillus and / or its metabolites according to the first aspect of the present invention; and (b) a pharmaceutically acceptable carrier or a food acceptable carrier.

[0009] In another preferred embodiment, the metabolites include non-protein substances with a molecular weight of less than 3 KDa.

[0010] In another preferred embodiment, the metabolites include: culture supernatant.

[0011] In another preferred embodiment, the metabolites include: separated culture supernatant with a molecular weight less than 10 KDa, or separated culture supernatant with a molecular weight less than 3 KDa.

[0012] In another preferred embodiment, the metabolite is an ethyl acetate extract or an ether extract of the culture supernatant.

[0013] In another preferred embodiment, the metabolites include: Fig.21 ) metabolites (the molecular formula of the compound may be C 21 H 25 N7O3 or C 20 H 29 N3O7).

[0014] In another preferred embodiment, the culture supernatant includes the culture supernatant obtained by culturing with a basal medium (such as M9 medium) or a non-basic medium.

[0015] In another preferred embodiment, the metabolites include ether extraction products of the Bacillus culture supernatant according to the first aspect of the present invention.

[0016] In another preferred embodiment, the metabolites include ethyl acetate extraction products of the Bacillus culture supernatant according to the first aspect of the present invention.

[0017] In another preferred embodiment, the culture is cultured using M9 medium.

[0018] In another preferred embodiment, the composition is selected from the following group: a pharmaceutical composition, a food composition, a health care composition, a beverage composition, a feed composition, or a combination thereof.

[0019] In another preferred embodiment, the composition is an oral preparation.

[0020] In another preferred embodiment, the composition is a liquid preparation, a solid preparation, or a semi-solid preparation.

[0021] In another preferred embodiment, the dosage form of the composition is selected from the group consisting of powders, powders, tablets, sugar-coated tablets, capsules, granules, suspensions, solutions, syrups, drops, and sublingual tablets.

[0022] In another preferred embodiment, the food composition includes an emulsion product, a solution product, a powder product, or a suspension product.

[0023] In another preferred embodiment, the food composition includes dairy products, milk powder, or emulsion.

[0024] In another preferred embodiment, the liquid preparation is selected from the following group: a solution preparation or a suspension preparation.

[0025] In another preferred embodiment, the composition contains 1×10-1×10 20 cfu / mL or cfu / g of the Bacillus as described in the first aspect of the present invention, preferably 1×104 -1×10 15 cfu / mL or cfu / g of the Bacillus, based on the total volume or weight of the composition.

[0026] In another preferred embodiment, the composition contains 0.0001-99 wt %, preferably 0.1-90 wt % of the Bacillus and / or its metabolites, based on the total weight of the composition.

[0027] In another preferred embodiment, the composition is in unit dosage form (a tablet, a capsule or a vial), and the mass of the composition in each unit dosage form is 0.05-5g, preferably 0.1-1g.

[0028] In another preferred embodiment, the composition further contains other probiotics and / or prebiotics.

[0029] In another preferred embodiment, the probiotics are selected from the following group: lactic acid bacteria, bifidobacteria, Lactobacillus acidophilus, or a combination thereof.

[0030] In another preferred embodiment, the prebiotic is selected from the group consisting of fructooligosaccharides (FOS), galacto-oligosaccharides (GOS), xylooligosaccharides (XOS), lactofructooligosaccharides (LACT), soy oligosaccharides (SOS), inulin, or a combination thereof.

[0031] The third aspect of the present invention provides a use of the Bacillus described in the first aspect of the present invention or the composition described in the second aspect of the present invention for preparing a medicament for preventing and / or treating viral infection.

[0032] In another preferred embodiment, the prevention and / or treatment of viral infection is the inhibition of viral infection.

[0033] In another preferred embodiment, the virus is selected from: influenza virus, herpes simplex virus (HSV), enterovirus, or a combination thereof.

[0034] In another preferred embodiment, the influenza virus is selected from: influenza virus PR8 strain, G2 H3N2, HK H3N2, California H1N1, H9N2, H4N2, or a combination thereof.

[0035] In another preferred embodiment, the herpes simplex virus includes herpes simplex virus type 1 (HSV-1).

[0036] In another preferred embodiment, the enterovirus includes EV71.

[0037] The fourth aspect of the present invention provides a use of the Bacillus described in the first aspect of the present invention or the composition described in the second aspect of the present invention, characterized in that it is used to prepare a drug or preparation, and the drug or preparation is used to prevent and / or treat viral infection.

[0038] In another preferred embodiment, the prevention and / or treatment of viral infection is the inhibition of viral infection.

[0039] In another preferred embodiment, the virus is selected from: influenza virus, herpes simplex virus (HSV), enterovirus, or a combination thereof.

[0040] In another preferred embodiment, the influenza virus is selected from: influenza virus PR8 strain, G2 H3N2, HK H3N2, California H1N1, H9N2, H4N2, or a combination thereof.

[0041] In another preferred embodiment, the herpes simplex virus includes herpes simplex virus type 1 (HSV-1).

[0042] In another preferred embodiment, the enterovirus includes EV71.

[0043] In another preferred embodiment, the mammals include humans and rodents (such as rats and mice).

[0044] The fifth aspect of the present invention provides a method for preparing the composition according to the second aspect of the present invention, characterized in that it comprises the steps of:

[0045] The bacillus and / or its metabolites described in the first aspect of the present invention are mixed with a pharmaceutically acceptable carrier or a food acceptable carrier to form the composition described in the second aspect of the present invention.

[0046] In another preferred embodiment, the composition is an oral preparation.

[0047] The sixth aspect of the present invention provides a production method, characterized in that it comprises the steps of:

[0048] (a) culturing the bacillus described in the first aspect of the present invention under conditions suitable for cultivation, thereby obtaining a culture product;

[0049] (b) optionally, isolating Bacillus cells and / or metabolites thereof from the culture product; and

[0050] (c) Optionally, the Bacillus cells and / or metabolites thereof separated and obtained in the previous step are mixed with a pharmaceutically acceptable carrier or a food acceptable carrier to prepare a composition.

[0051] The seventh aspect of the present invention provides an in vitro method for inhibiting viruses, characterized in that a safe and effective amount of the Bacillus described in the first aspect of the present invention is administered.

[0052] In another preferred embodiment, the method is non-diagnostic and non-therapeutic.

[0053] The eighth aspect of the present invention provides a method for inhibiting viruses in vivo, characterized in that a safe and effective amount of the Bacillus described in the first aspect of the present invention or the composition described in the second aspect of the present invention is administered to the subject.

[0054] In another preferred embodiment, the administration comprises oral administration.

[0055] In another preferred embodiment, the dosage is 1×10-1×10 20 cfu / mL or cfu / g of the Bacillus as claimed in claim 1, preferably 1×10 4 -1×10 15 cfu / mL or cfu / g of Bacillus

[0056] In another preferred embodiment, the subject weighs 30-150 kg, preferably 40-100 kg.

[0057] In another preferred embodiment, the subject includes mammals, such as humans and non-human mammals.

[0058] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1 Phylogenetic tree constructed based on the 16S rRNA gene sequence of LYM3. Phylogenetic tree based on 16S rRNA gene sequence using the neighbor-joining method in MEGA8. The two values ​​at each node represent the bootstrap percentages of 1,000 resamplings.

[0060] Figure 2 LYM3 nuclear genome circle diagram. From outside to inside, it is coding gene (positive strand), coding gene (negative strand), tRNA (orange) and rRNA (purple), CRISPR (blue) and gene island (green), GC ratio, GC-skew, and sequencing depth.

[0061] Figure 3LYM3 bacterial growth curve. Pick a single LYM3 colony, activate it by shaking for 18 hours, and then inoculate it into BHI medium at a ratio of 1%, and culture it at 37°C and 225rpm. Use a spectrophotometer to test the OD600 value of the bacterial solution at different culture times to determine the growth curve of the LYM3 strain.

[0062] Figure 4 LYM3 supernatant cannot inhibit the adsorption of influenza virus PR8 strain. (AB) After pre-incubation of MDCK cells (A) and A549 cells (B) with different concentrations of LYM3 supernatant for 30 minutes, influenza virus PR8 strain was added for infection at 4℃ for 1 hour, and the content of viral M1 gene on the cells was detected by QPCR after 1 hour.

[0063] Figure 5 LYM3 supernatant cannot inhibit the replication of influenza virus PR8 strain. (AB) After 6 hours of infection of MDCK (A) and A549 cells (B) with influenza virus PR8 strain, the virus was washed away, and different concentrations of LYM3 supernatant were added. After infection for another 18 hours, the content of viral M1 gene in the cells was detected by QPCR.

[0064] Figure 6 LYM3 supernatant inhibits viral entry at 6h of influenza virus PR8 infection. (AB) MDCK cells (A) and A549 cells (B) were pre-incubated with different concentrations of LYM3 supernatant for 30min, and then influenza virus PR8 was added for infection for 6h. After 6h, the content of viral M1 gene in cells was detected by QPCR. (C) MDCK cells were pre-incubated with different concentrations of LYM3 supernatant for 30min, and then influenza virus PR8 was added for infection for 6h. After 6h, the content of influenza virus NP / HA / M1 protein in cells was detected by Western blot. (D) MDCK cells were infected with the cell supernatant in (A), and the amount of virus in cells was detected 65h later.

[0065] Figure 7LYM3 supernatant inhibits viral entry at 3h after infection with influenza virus PR8 strain. (AB) MDCK (A) and A549 (B) were pre-infected with influenza virus PR8 strain for 1h, the virus was washed away after 1h, different concentrations of LYM3 supernatant were added, and the content of viral M1 gene in cells was detected by QPCR 3h later. (C, F) MDCK (C) and A549 (F) were pre-infected with influenza virus PR8 strain for 1h, the virus was washed away after 1h, different concentrations of LYM3 supernatant were added, and the content of influenza virus NP / M1 protein in cells was detected by Western blot 3h later. (DE) MDCK cells were infected with the cell supernatant in (B) in (D), and the amount of virus in the cells was detected 65h later; (E) MDCK cells were infected with the cell supernatant in (F), and the amount of virus in the cells was detected 65h later.

[0066] Figure 8 LYM3 supernatant inhibits virus entry 2 hours after influenza virus PR8 strain pre-infection. MDCK cells were pre-infected with influenza virus PR8 strain for 2 hours, the virus was washed away after 2 hours, different concentrations of LYM3 supernatant were added, and the content of viral M1 gene in the cells was detected by QPCR after 4 / 10 hours.

[0067] Fig. 9 Effect of intranasal LYM3 supernatant on body weight and mortality of mice infected with influenza virus. Wild-type female mice aged 7 weeks were used for animal experiments. LYM3 supernatant was instilled into the nose 30 minutes (AB) before infection with influenza virus PR8 strain and 30 minutes (CD), 2 hours (EF), and 12 hours (GH) after infection with influenza virus PR8 strain. The weight changes and survival rates of mice were recorded within 15 days. Mice with a relative body weight lower than 75% of their original body weight were considered dead.

[0068] Fig.10 LYM3 supernatant inhibits herpes simplex virus type 1 (HSV-1) infection. Vero cells were pre-incubated with different concentrations of LYM3 supernatant for 30 minutes, and then HSV-1 virus was added for infection for 6 hours. After 6 hours, the viral load in the cells was detected by QPCR.

[0069] Fig.11 LYM3 supernatant inhibits enterovirus 71 (EV71) infection. RD cells were pre-incubated with different concentrations of LYM3 supernatant for 30 min, then EV71 virus was added for infection for 6 h, and the viral load in the cells was detected by QPCR after 6 h.

[0070] Fig.12LYM3 supernatant loses its antiviral function after high temperature treatment. MDCK cells were pre-incubated with high temperature treated LYM3 supernatant and untreated LYM3 supernatant for 30 minutes, then infected with influenza virus PR8 strain for 6 hours, and the content of viral M1 gene in cells was detected by QPCR after 6 hours.

[0071] Fig.13 Functional components are less than 10KDa. (A) After pre-incubation of MDCK cells with LYM3 components greater than 10KDa and LYM3 components less than 10KDa for 30 minutes, the cells were infected with influenza virus PR8 strain for 6 hours, and the content of viral M1 gene in the cells was detected by QPCR after 6 hours. (B) After pre-incubation of MDCK cells with LYM3 components greater than 10KDa and LYM3 components less than 10KDa for 30 minutes, the cells were infected with influenza virus PR8 strain for 6 hours, and the content of influenza virus NP / HA / M1 protein in the cells was detected by Western blot after 6 hours.

[0072] Fig.14 Functional components are less than 3KDa. (A) After pre-incubation of MDCK cells with LYM3 components of 3-10KDa and less than 3KDa for 30 minutes, the cells were infected with influenza virus PR8 strain for 6 hours, and the content of viral M1 gene in the cells was detected by QPCR after 6 hours. (B) After pre-incubation of MDCK cells with LYM3 components of 3-10KDa and less than 3KDa for 30 minutes, the cells were infected with influenza virus PR8 strain for 6 hours, and the content of influenza virus NP / HA / M1 protein in the cells was detected by Western blot after 6 hours.

[0073] Fig.15 The protein components in the LYM3 supernatant have no antiviral function. After pre-incubating MDCK cells with the protein components of the LYM3 supernatant for 30 minutes, they were infected with the influenza virus PR8 strain for 6 hours, and the content of the viral M1 gene in the cells was detected by QPCR after 6 hours.

[0074] Fig.16 Functional components are not proteins. (A) Using a protein-free flowthrough and a protein smaller than 3KDa, the two components were pre-incubated in MDCK cells for 30 minutes, and then infected with influenza virus PR8 strain for 6 hours. After 6 hours, the content of viral M1 gene in the cells was detected by QPCR. (B) Using a protein-free flowthrough and a protein smaller than 3KDa, the two components were pre-incubated in MDCK cells for 30 minutes, and then infected with influenza virus PR8 strain for 6 hours. After 6 hours, the content of influenza virus NP / HA / M1 protein in the cells was detected by Western blot.

[0075] Fig.17Antiviral function experiment of organic solvent extraction products. MDCK cells were pre-incubated with different organic solvent extraction products of LYM3 supernatant for 30 minutes, and then infected with influenza virus PR8 strain for 6 hours. After 6 hours, the content of viral M1 gene in the cells was detected by QPCR.

[0076] Fig.18 Analysis of the antiviral function of M9 LYM3 supernatant. MDCK cells were pre-incubated with M9-LYM3 supernatant for 30 minutes and then infected with influenza virus PR8 strain for 6 hours. After 6 hours, the content of viral M1 gene in the cells was detected by QPCR.

[0077] Fig.19 Analysis of the antiviral function of M9-LYM3 ethyl acetate extract at different dilutions. MDCK cells were pre-incubated with M9-LYM3 ethyl acetate extract at different dilutions for 30 minutes, and then infected with influenza virus PR8 strain for 6 hours. After 6 hours, the content of viral M1 gene in the cells was detected by QPCR.

[0078] Fig. 20 Analysis of the antiviral function of HPLC separation components. (A) After pre-incubation of MDCK cells with HPLC separation products of 0-10min, 10-20min, and 20-30min for 30min, the PR8 strain of influenza virus was infected for 6h, and the content of viral M1 gene in the cells was detected by QPCR after 6h. (B) After pre-incubation of MDCK cells with HPLC separation products of 11min, 12min, 13min, 14min, 15min, 16min, 17min, 18min, 19min, and 20min for 30min, the PR8 strain of influenza virus was infected for 6h, and the content of viral M1 gene in the cells was detected by QPCR after 6h.

[0079] Fig.21 LC-MS / MS result analysis: Agilent ultra-high performance liquid chromatograph, Q Exactive plus (Orbitrap), C18 column, HPLC conditions were water / acetonitrile (10-100%), 0.1% formic acid, flow rate 1 mL / min. DDA analysis was performed in both forward and reverse modes.

[0080] Fig. 22 The active ingredients in the supernatant of LYM3 inhibit infection by other influenza virus subtypes. (AE) After pre-incubation of MDCK cells with the active ingredient (BSD20) in the supernatant of LYM3 for 30 minutes, they were infected with influenza viruses G2 H3N2 (A), HK H3N2 (B), California H1N1 (C), H9N2 (D), and H4N2 (E) for 6 hours. After 6 hours, the content of the viral M1 gene in the cells was detected by QPCR. DETAILED DESCRIPTION

[0081] The inventors, through extensive and in-depth research and a large number of screenings, unexpectedly isolated and identified a new Bacillus strain LYM3, and proved through experiments that the strain has antiviral function.

[0082] Specifically, the inventors determined the genome sequence of LYM3 and confirmed its anti-influenza function and anti-other virus function. The in vitro fermentation supernatant of the strain can significantly inhibit the entry of the influenza virus PR8 strain in in vitro experiments, and can accelerate the weight recovery and improve the survival rate of influenza-infected mice in animal experiments. In addition, the in vitro fermentation supernatant of the strain can also significantly inhibit the infection of HSV-1 and EV71 viruses in in vitro experiments. In addition, it was found that the functional component in the LYM3 supernatant is a small molecule that is sensitive to high temperature, less than 3KDa, and not a protein. Through organic solvent extraction, it was found that the ethyl acetate extract of the LYM3 supernatant has anti-influenza virus function.

[0083] On this basis, the present invention has been completed.

[0084] the term

[0085] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0086] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".

[0087] Sequence identity is determined by comparing two aligned sequences along a predetermined comparison window (which can be 50%, 60%, 70%, 80%, 90%, 95% or 100% of the length of the reference nucleotide sequence or protein) and determining the number of positions at which identical residues occur. Typically, this is expressed as a percentage. The measurement of sequence identity of nucleotide sequences is a method well known to those skilled in the art.

[0088] The strain of the present invention and its application

[0089] As used herein, the terms "strain of the present invention", "Bacillus strain LYM3 of the present invention", and "Bacillus strain LYM3" are used interchangeably, referring to Bacillus zhangzhouensisLYM3 with antiviral function isolated by the inventors, which is deposited in CCTCC with the deposit number of CCTCC M2023870. It should be understood that the strain of the present invention also includes Bacillus strains with the same or substantially the same properties (especially antiviral function) obtained by culturing or amplifying the deposited strain.

[0090] Based on the sequence analysis of 16S rRNA, the strain of the present invention belongs to Bacillus, which is an endospore-forming Gram-positive bacterium.

[0091] The bacillus of the present invention can produce a variety of different metabolites, including (but not limited to): small molecules, peptides, enzymes, extracellular polymers, etc. The research of the present invention shows that the strain of the present invention and its metabolites have antiviral function.

[0092] The invention also provides the application of the strain and its metabolites in anti-virus.

[0093] Pharmaceutical composition

[0094] The present invention also provides a composition. In a preferred embodiment, the composition is a pharmaceutical composition, which contains an effective amount of the bacillus of the present invention and a pharmaceutically acceptable carrier. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, although the pH value may vary depending on the nature of the formulated substance and the condition to be treated.

[0095] In a preferred example, the composition is a liquid preparation, a solid preparation, or a semi-solid preparation.

[0096] In a preferred embodiment, the liquid preparation is selected from the following group: a solution preparation or a suspension preparation.

[0097] In a preferred embodiment, the dosage form of the composition is selected from the group consisting of powders, granules, tablets, sugar-coated tablets, capsules, granules, suspensions, solutions, syrups, drops, and sublingual tablets.

[0098] The pharmaceutical composition of the present invention can be administered in the form of tablets, injections or capsules, and the pharmaceutical preparation includes excipients, pharmaceutically acceptable media and carriers, which can be selected according to the route of administration. The pharmaceutical preparation of the present invention can further include auxiliary active ingredients.

[0099] Lactose, glucose, sucrose, sorbitol, mannose, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, fine crystalline cellulose, polyvinyl pyrrolidone (PVP), cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate or mineral oil can be used as carriers, excipients or diluents of the pharmaceutical composition of the present invention.

[0100] In addition, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, emulsifiers, suspension stabilizers, preservatives, sweeteners and flavors, etc. The pharmaceutical composition of the present invention can be produced as an enteric coating preparation by various well-known methods so that the active ingredient of the pharmaceutical composition, i.e., the microorganism, can pass through the stomach smoothly without being destroyed by gastric acid.

[0101] In addition, the microorganism of the present invention can be used in the form of capsules prepared by conventional methods. For example, standard excipients and freeze-dried microorganisms of the present invention are mixed to form pellets, which are then filled into gelatin capsules. In addition, microorganisms of the present invention and drugs that allow the use of excipients such as liquid glue, cellulose, silicate or mineral oil are mixed to make suspensions or dispersions, which can be loaded into soft gelatin capsules.

[0102] The pharmaceutical composition of the present invention can be made into enteric-coated tablets for oral use. The term "enteric coating" in this application includes all coatings allowed for use in conventional drugs, which are not degraded by gastric acid but can be fully decomposed in the small intestine and quickly release the microorganisms of the present invention. The enteric coating of the present invention can be maintained at 36-38°C for more than 2 hours in synthetic gastric acid such as HCl solution with pH=1, and preferably decomposed within 1.0 hour in synthetic intestinal fluid such as buffer with pH=7.0.

[0103] The enteric coating of the present invention is coated with about 16-30 mg per tablet, preferably 16-25 mg, and more preferably 16-20 mg. The thickness of the enteric coating of the present invention is 5-100 μm, and the ideal thickness is 20-80 μm. The enteric coating components are selected from conventional polymers that are publicly known.

[0104] The preferred enteric casing of the present invention is prepared from a copolymer of cellulose acetate phthalate polymer or trimellitate polymer and methacrylic acid (for example, a copolymer of methacrylic acid containing more than 40% methacrylic acid and methylcellulose hydroxypropyl phthalate or its ester derivatives).

[0105] The viscosity of cellulose acetate phthalate used in the casing of the present invention is about 45-90 cp (Pascal (Pas), abbreviated as cp), the acetyl content is 17-26%, and the phthalic acid content is 30-40%. The viscosity of cellulose acetate trimellitate used in the casing is about 5-21 cs (centistokes), and the acetyl content is 17-26%. Cellulose acetate trimellitate is produced by Eastman Kodak Company and can be used for the casing material of the present invention.

[0106] The hydroxypropyl methylcellulose phthalate used in the enteric coating of the present invention generally has a molecular weight of 20,000-130,000 Daltons, an ideal molecular weight of 80,000-100,000 Daltons, a hydroxypropyl content of 5-10%, a methoxy content of 18-24%, and a phthaloyl content of 21-35%.

[0107] The hydroxypropyl methylcellulose phthalate used in the enteric coating of the present invention is HP50, produced by Shin-Etsu Chemidnl Co. Ltd. of Japan. HP50 contains 6-10% hydroxypropyl, 20-24% methoxy, 21-27% propyl, and its molecular weight is 84,000 Daltons. Another enteric coating material is HP55, which contains 5-9% hydroxypropyl methylcellulose phthalate, 18-22% methoxy, 27-35% phthalic acid, and its molecular weight is 78,000 Daltons.

[0108] The enteric coating of the present invention is prepared as follows: the enteric coating solution is sprayed onto the core using conventional methods. All solvents in the enteric coating method are alcohols (such as ethanol), ketones (such as acetone), halogenated hydrocarbon compounds (such as dichloromethane), or combinations thereof. Softeners such as di-n-butyl phthalate and triacetin are added to the enteric coating solution in a ratio of 1 part of coating to about 0.05 or about 0.3 parts of softener. The spraying method is preferably performed continuously, and the amount of material sprayed can be controlled according to the conditions used for coating. The spray pressure can be adjusted at will, and generally speaking, ideal results can be obtained at an average pressure of 1-1.5 bar.

[0109] In the specification, "pharmaceutically effective amount" refers to an amount that can produce functions or activities on humans and / or animals and can be accepted by humans and / or animals. For example, in the present invention, a drug containing 1×10-1×10 20 cfu / ml or cfu / g (particularly, it may contain 1×10 4 -1×10 15 cfu / ml or cfu / g; more specifically, it may contain 1×10 6 -1×10 11 cfu / ml or cfu / g) of Bacillus and / or its metabolites.

[0110] When used to prepare a pharmaceutical composition, the effective dose of the bacillus or its metabolites used may vary depending on the mode of administration and the severity of the disease to be treated. The dosage form suitable for oral administration comprises about 1×10-1×10 20 cfu / ml or cfu / g (particularly, it may contain 1×10 4 -1×10 15 cfu / ml or cfu / g; more specifically, it may contain 1×10 6 -1×10 11 cfu / ml or cfu / g) of active bacillus or active ingredients produced by fermentation. This dosage regimen can be adjusted to provide the best therapeutic response. For example, several divided doses can be given daily, or the dose can be reduced proportionally, depending on the urgency of the therapeutic situation.

[0111] The bacillus or its metabolites can be administered orally or other routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include culture media, polyethylene glycol, nonionic surfactants and edible oils (such as corn oil, peanut oil and sesame oil), as long as they are suitable for the characteristics of the bacillus or its metabolites and the specific administration method required. Adjuvants commonly used in the preparation of pharmaceutical compositions may also be advantageously included, such as flavoring agents, pigments, preservatives and antioxidants such as vitamin E, vitamin C, BHT and BHA.

[0112] From the standpoint of ease of preparation and administration, preferred pharmaceutical compositions are solid compositions, especially tablets and solid-filled or liquid-filled capsules. Oral administration is preferred.

[0113] The composition of the present invention is administered to the individual once or more per day. The dosage unit represents a dosage that can be separated in form and is suitable for humans or all other mammalian individuals. Each unit contains a pharmaceutically acceptable carrier and an effective therapeutic amount of the microorganism of the present invention. The dosage varies with the patient's weight and obesity severity, the supplementary active components included and the microorganisms used. In addition, if possible, the administration can be separated, and if necessary, it can be continuously administered. Therefore, the dosage does not limit the present invention. In addition, the "composition" in the present invention not only means a medicine but also means that it can be used as a functional food and a health supplement food. In a preferred embodiment, the composition includes: beverages, food, medicines, animal feed, etc.

[0114] In a preferred embodiment of the present invention, a food composition is also provided, which contains an effective amount of Bacillus and / or its metabolites, and the remainder is a food acceptable carrier, and the dosage form of the food composition is selected from solid, dairy, solution products, powder products, or suspension products.

[0115] In a preferred embodiment, the composition has the following formula:

[0116] 1×10-1×10 20 cfu / mL of Bacillus and / or its metabolites; and a food or pharmaceutically acceptable carrier, and / or excipient.

[0117] In another preferred embodiment, the composition has the following formula:

[0118] 1×10 6 -1×10 11 cfu / mL of Bacillus and / or its metabolites; and a food or pharmaceutically acceptable carrier, and / or excipient.

[0119] The method of the present invention may further include administering the preparation or composition of the present invention and one or more antiviral drugs to a subject infected with a virus. The antiviral drug may be administered in combination with the preparation or composition of the present invention or separately from the preparation or composition of the present invention. The administration of the preparation or composition of the present invention and the one or more antiviral drugs may be separate, simultaneous, overlapping or sequential.

[0120] The preparation or composition of the present invention has antiviral activity. The virus can be selected from, but not limited to: positive-strand single-stranded RNA virus ((+)-ss-envRNAV), negative-strand single-stranded RNA virus ((-)-ss-envRNAV), and double-stranded DNA virus (ds-DNAV).

[0121] In some embodiments, the family to which the virus belongs can be selected from, but is not limited to, Arenavirus, Arterviridae, Bunyavirus, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Retroviridae (particularly the genus Deltaretroviridae), Coronaviridae, Togaviridae, Herpesviridae, Poxviridae, or Hepadnaviridae.

[0122] In some embodiments, the (+)-ss-envRNAV can be selected from, but not limited to, viruses of the Coronavirus family, Flaviviridae family, Togaviridae family, and Arterviridae family. In some embodiments, the (+)-ss-envRNAV can be a coronavirus pathogenic to humans.

[0123] In some embodiments, the (+)-ss-envRNAV can be selected from but not limited to: flavivirus, yellow fever virus, dengue virus, Japanese Enchephalitis virus, West Nile virus, Zika virus, Tick-borne Encephalitis virus, Kyasanur Forest Disease Virus, Alkhurma Disease Virus, Omsk Hemorrhagic Fever Virus, and Powassan Virus.

[0124] In some embodiments, the (+)-ss-envRNAV can be a Togaviridae virus, selected from but not limited to: arborvirus, Eastern equine encephalitis virus (EEEV), Western equine encephalitis virus (WEEV), Venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV), O'nyong'nvirus (ONNV), Pogosta disease virus, Sindbis virus, Ross River fever virus (RRV) and Semiliki Forest virus.

[0125] In some embodiments, the (-)-(ss)-envRNAV virus can be selected from, but not limited to, the Arenaviridae family, the Bunyaviridae family (order Bunyavirales), the Filoviridae family, the Orthomyxoviridae family, the Paramyxoviridae family, or the Rhabdoviridae family.

[0126] In some embodiments, the Arenaviridae virus can be selected from, but is not limited to, Lassa virus, aseptic mengitis virus, Guanarito virus, Junin virus, Lujo virus, Machupo virus, Sabia virus, and Whitewater Arroyo virus.

[0127] In some embodiments, the Bunyaviridae family virus can be selected from, but not limited to, Hantavirus and Crimean-Congo hemorrhagic fever orthonairovirus.

[0128] In some embodiments, the Paramyxoviridae virus can be selected from, but not limited to, mumps virus, Nipah virus, Hendra virus, respiratory syncytial virus (RSV), human parainfluenza virus (HPIV), and NDV.

[0129] In some embodiments, the Orthomyxoviridae virus can be selected from, but not limited to, influenza virus (type A (A) to type C (C)), Isavirus, Thogotovirus, Quaranjavirus, H1N1 virus, H2N2 virus, H3N2 virus, H1N2 virus, Spanish flu virus, Asian flu virus, and Russian flu virus.

[0130] In some embodiments, the Rhabdoviridae family virus can be selected from, but not limited to, rabies virus, vesiculovirus, and Cytorhabdovirus.

[0131] Production method of bacillus of the present invention

[0132] Generally, in the case where the strain of the present invention is provided, the Bacillus of the present invention can be prepared or amplified by conventional methods.

[0133] Preferably, the present invention provides a method for large-scale production of the Bacillus of the present invention, specifically, comprising the following steps:

[0134] (a) culturing the bacillus of the present invention under conditions suitable for culturing, thereby obtaining a culture product;

[0135] (b) optionally, isolating Bacillus cells and / or metabolites thereof from the culture product; and

[0136] (c) Optionally, the Bacillus cells and / or their metabolites separated in the previous step are mixed with a food-acceptable carrier or a pharmaceutically acceptable carrier to prepare a composition.

[0137] The main advantages of the present invention include:

[0138] (a) It has a significant inhibitory effect on the infection of many viruses.

[0139] (b) It can effectively inhibit influenza virus infection both in vivo and in vitro.

[0140] (c) Inhibits virus entry into host cells and is safe in mouse experiments.

[0141] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0142] Unless otherwise specified, the materials and reagents used in the examples of the present invention are commercially available products.

[0143] Example 1 Isolation and Identification of LYM3 Strain

[0144] 1.1 Isolation and taxonomic status of LYM3 strain

[0145] The LYM3 strain was isolated from the Chinese herbal medicine Ephedra sinica. The strain was cultured in BHI liquid medium (Brain Heart Infusion, BHI, Beijing Biode Biotech Co., Ltd.).

[0146] The LYM3 strain has eight 16S rRNA genes, and their full-length nucleic acid sequences are shown in Table 1. The NCBI database was used to compare and analyze the full-length sequences of the 16S rRNA genes of the strain and to construct a phylogenetic tree ( Figure 1 ), the results showed that the strain was highly similar to Bacillus. Therefore, it can be determined that the strain is a new Bacillus strain.

[0147] The whole genome sequencing of the LYM3 strain showed that the bacterium contained an RNA genome (tRNA: 81; 5SrRNA: 8; 16SrRNA: 8; 23SrRNA: 8) with 3666 CDS. The genome sequencing depth, GC distribution, GC-skew and genome structure annotation were integrated to draw the nuclear genome circle map as follows ( Figure 2 ). From outside to inside, they are coding gene (positive strand), coding gene (negative strand), tRNA (orange) and rRNA (purple), CRISPR (blue) and gene island (green), GC ratio, GC-skew, and sequencing depth. The statistics of genome structure prediction are shown in Table 2.

[0148] Table 1 Full-length nucleic acid sequences of eight 16S rRNA genes of LYM3

[0149]

[0150]

[0151]

[0152] Table 2. LYM3 genome structure prediction statistics

[0153]

[0154] 1.2 LYM3 bacterial growth curve determination

[0155] The results of bacterial growth curve showed that the LYM3 strain entered the plateau phase after 8 hours of culture ( Figure 3 ).

[0156] 1.3 Preparation of LYM3 supernatant

[0157] (1) Use a clean inoculation loop to pick fresh LYM3 colonies from the LYM3 plate and inoculate them into BHI liquid culture medium. Incubate for 18 h at 37°C and 225 rpm in a shaking incubator.

[0158] (2) Inoculate at a ratio of 1% by adding 100 μl of bacterial solution to 10 ml of liquid culture medium and incubate on a shaking platform for 8 h at 37°C and 225 rpm.

[0159] (3) Collect the LYM3 bacterial solution after 8 hours of culture and pour it into a 50 ml centrifuge tube. Centrifuge it at 37°C and 3500 rpm for 10 minutes. Pour the bacterial solution after centrifugation into a new 50 ml centrifuge tube and repeat the centrifugation.

[0160] (4) Filter the bacterial solution using a 0.22 μm filter to obtain the LYM3 supernatant, which is then stored in a -80°C refrigerator until use.

[0161] Example 2 LYM3 supernatant protects against influenza virus infection

[0162] 2.1LYM3 supernatant cannot inhibit the adsorption process of influenza virus

[0163] In this example, a concentration-dependent experiment was conducted on the antiviral effect of LYM3 supernatant on influenza virus adsorption. The method is as follows: MDCK / A549 cells were pre-incubated with different concentrations of LYM3 supernatant / medium for 30 minutes, and then influenza virus PR8 strain was added and infected at 4°C for 1 hour.

[0164] The results of real-time fluorescence quantitative PCR experiments showed that compared with the medium group, the content of viral M1 gene on the cells did not gradually decrease with the increase of LYM3 supernatant concentration. Even in the 4% concentration of LYM3 supernatant, it was unable to inhibit the adsorption of influenza virus PR8 strain ( Figure 4 A, B). This indicates that the LYM3 supernatant cannot inhibit the adsorption process of influenza virus PR8 strain.

[0165] 2.2LYM3 supernatant cannot inhibit influenza virus replication

[0166] In this example, a concentration-dependent experiment was conducted on the antiviral effect of LYM3 supernatant during the influenza virus replication stage. The method is as follows: MDCK / A549 cells were infected with influenza virus PR8 strain for 6 hours, the virus was washed away, different concentrations of LYM3 supernatant / medium were added, and infection was continued for 18 hours.

[0167] The results of real-time fluorescence quantitative PCR experiments showed that compared with the medium group, the content of viral M1 gene in cells did not gradually decrease with the increase of LYM3 supernatant concentration. Even in the 4% concentration of LYM3 supernatant, the replication of influenza virus PR8 strain could not be inhibited ( Figure 5 A, B). This indicates that LYM3 supernatant cannot inhibit the replication of influenza virus PR8 strain.

[0168] 2.3LYM3 supernatant inhibits influenza virus PR8 infection at the virus entry stage

[0169] 2.3.1 Pretreatment followed by influenza virus infection

[0170] MDCK / A549 cells were pre-incubated with different concentrations of LYM3 supernatant / medium for 30 min and then infected with influenza virus PR8 strain for 6 h.

[0171] The results of real-time fluorescence quantitative PCR showed that compared with the medium group, as the concentration of LYM3 supernatant increased, the content of viral M1 gene in the cells gradually decreased, showing a concentration gradient dependence ( Figure 6 A, B). This indicates that LYM3 supernatant inhibited the entry of influenza virus PR8 strain at 6 h of virus infection.

[0172] The same results were obtained by immunoblotting experiments. In MDCK cells, as the concentration of LYM3 supernatant increased, the viral proteins NP, HA, and M1 in the cells were significantly reduced ( Figure 6 C).

[0173] At the same time, the amount of virus in the supernatant of MDCK cells in the QPCR experiment was detected by virus titration. The results showed that when the concentration of LYM3 supernatant gradually increased, the amount of virus outside the cells also gradually increased ( Figure 6 D), which is consistent with the experimental results of QPCR. When the LYM3 supernatant gradually inhibited the virus from entering the cells with increasing concentration, the amount of virus outside the cells also increased accordingly.

[0174] 2.3.2 Influenza virus infection followed by treatment with LYM3 supernatant

[0175] (a) MDCK / A549 cells were infected with influenza virus PR8 strain for 1 h. After 1 h of virus infection, the virus was washed away with PBS buffer, and different concentrations of LYM3 supernatant were added and infected again in a 37°C incubator for 3 h.

[0176] The results of real-time fluorescence quantitative PCR experiments showed that as the concentration of LYM3 supernatant increased, the content of viral M1 gene in cells gradually decreased, showing a concentration gradient dependence ( Figure 7 A, B). This indicates that LYM3 supernatant inhibited the entry of influenza virus PR8 strain at 3 h of virus infection.

[0177] The same results were obtained by immunoblotting experiments. In MDCK cells, as the concentration of LYM3 supernatant increased, the viral proteins NP and M1 in the cells were significantly reduced ( Figure 7 C, F).

[0178] At the same time, the amount of virus in the supernatant of MDCK / A549 cells in the QPCR experiment was detected by virus titration. The results showed that when the concentration of LYM3 supernatant gradually increased, the amount of virus outside the cells also gradually increased ( Figure 7 D, E), which is consistent with the experimental results of QPCR. When the LYM3 supernatant gradually inhibits the entry of the virus into the cells with the increase of concentration, the amount of virus outside the cells also increases accordingly.

[0179] (b) To further prove that LYM3 supernatant inhibits the infection of influenza virus PR8 strain at the entry stage, MDCK cells were first infected with influenza virus PR8 strain for 2 h. After 2 h of virus infection, the virus was washed away with PBS buffer, and different concentrations of LYM3 supernatant were added, and the cells were infected again for 4 h / 10 h in a 37°C incubator.

[0180] The results of real-time fluorescence quantitative PCR experiments showed that compared with the medium group, with the increase of LYM3 supernatant concentration, the content of viral M1 gene in cells gradually decreased, which was concentration gradient dependent. This shows that LYM3 supernatant can still significantly inhibit the entry of the virus 2h after the influenza virus PR8 strain pre-infected the cells ( Figure 8 ).

[0181] 2.4LYM3 supernatant inhibits influenza virus PR8 infection in vivo

[0182] In vivo animal experiments were performed using 7-week-old female C57BL / 6J mice from Weitong Lihua Laboratory Animal Technology Co., Ltd. The mice were transferred to an animal biosafety level 2 (ABSL2) laboratory for infection experiments. The mice were randomly divided into two groups and inoculated with PR8 / medium (BHI medium) and PR8 / LYM3 (bacterial supernatant). Anesthetic: Avertin, the concentration was 1.25%. Avertin was used for anesthesia when inoculating influenza virus PR8; isoflurane was used for anesthesia when LYM3 supernatant / medium was dripped into the nose. LYM3 supernatant is the supernatant of LYM3 cultured in BHI medium for 8 hours. The titer of influenza virus PR8 was 1.35×109pfu / ml, and 25μl was inoculated after dilution 40000 times. 25μl LYM3 supernatant was inoculated by intranasal drops 30min before inoculation of influenza virus PR8, and 30min, 2h, 12h, and 24h after inoculation of influenza virus PR8, and medium (BHI medium) was used as a control. The weight of the mice was recorded before the experiment. The weight of the mice was recorded within 15 days, and the mice whose relative weight was less than 75% of their original weight were considered dead.

[0183] The results of animal experiments showed that compared with the medium group, the addition of LYM3 supernatant 30 minutes before, 30 minutes, 2 hours, and 12 hours after influenza virus PR8 strain infection significantly reduced the weight loss and mortality of mice, and successfully protected the mice ( Fig. 9 AH). The in vivo experimental results show that LYM3 supernatant has antiviral function in the early stage of influenza virus PR8 strain infection, which is consistent with the in vitro experimental results.

[0184] Example 3 LYM3 supernatant protects against other viral infections

[0185] 3.1 LYM3 supernatant inhibits herpes simplex virus type 1 (HSV-1) infection

[0186] In order to detect the antiviral effect of LYM3 supernatant on other viruses, Vero cells were pre-incubated with LYM3 supernatant for 30 minutes and then infected with HSV-1 virus for 6 hours.

[0187] The results of real-time fluorescence quantitative PCR experiments showed that LYM3 supernatant significantly inhibited the infection of HSV-1 virus, and as the concentration of LYM3 supernatant increased, its antiviral function became stronger ( Fig.10 ).

[0188] 3.2 LYM3 supernatant inhibits enterovirus 71 (EV71) infection

[0189] RD cells were pre-incubated with LYM3 supernatant for 30 min and then infected with EV71 virus for 6 h.

[0190] The results of real-time fluorescence quantitative PCR experiments showed that LYM3 supernatant significantly inhibited the infection of EV71 virus, and as the concentration of LYM3 supernatant increased, its antiviral function became stronger ( Fig.11 ).

[0191] Example 4 Exploration of key functional components in LYM3 supernatant

[0192] 4.1LYM3 supernatant loses antiviral function after high temperature treatment

[0193] The active ingredients in the LYM3 supernatant are very complex. In order to determine its specific anti-influenza virus components, the antiviral function of the LYM3 supernatant was first tested after high temperature treatment. According to previous experimental results, the LYM3 supernatant inhibited the influenza virus PR8 strain at the 6h virus entry stage, so the subsequent antiviral function experiments all used a 6h infection time.

[0194] After pre-incubation of MDCK cells with high temperature treated LYM3 supernatant and untreated LYM3 supernatant for 30 min, the cells were infected with influenza virus PR8 strain for 6 h.

[0195] The results of real-time fluorescence quantitative PCR experiments showed that after high temperature treatment at 121°C for 20 minutes, even the 4% LYM3 supernatant lost all its antiviral function, while the LYM3 supernatant that had not been treated with high temperature still had significant antiviral function ( Fig.12 ). This result shows that the key antiviral component in the LYM3 supernatant is a substance that is sensitive to high temperature.

[0196] 4.2 Functional ingredients less than 10KDa

[0197] According to previous experiments, the inventors found that the functional components of the LYM3 supernatant were inactivated after high temperature treatment. It is assumed that this component is a protein that plays a role in inhibiting the infection of the influenza virus PR8 strain during the virus entry stage. The LYM3 supernatant was filtered using a 10KDa ultrafiltration tube to obtain two components: a LYM3 component greater than 10KDa and a LYM3 component less than 10KDa. After pre-incubating MDCK cells with these components (LYM3 components greater than 10KDa, LYM3 components less than 10KDa) for 30 minutes, the influenza virus PR8 strain was infected for 6 hours.

[0198] The results of real-time fluorescence quantitative PCR showed that after adding LYM3 components larger than 10KDa to MDCK cells, the content of viral M1 gene in the cells was not significantly different from that in the control group, but after adding LYM3 components smaller than 10KDa to MDCK cells, the content of viral M1 gene in the cells was significantly reduced ( Fig.13 A), which indicates that the LYM3 component smaller than 10 kDa has antiviral function.

[0199] At the same time, after high temperature treatment, the component smaller than 10KDa lost its antiviral function. The same results were obtained in the immunoblotting experiment. After adding the component smaller than 10KDa to MDCK cells, the NP / HA / M1 protein of the influenza virus PR8 strain was significantly reduced, and lost its antiviral ability after high temperature treatment ( Fig.13 B) These results indicate that the antiviral functional components in the LYM3 supernatant are less than 10 KDa.

[0200] 4.3 Functional ingredients less than 3KDa

[0201] According to the previous experimental results, the inventors found that the functional components in the LYM3 supernatant were less than 10KDa, so they continued to use a 3KDa ultrafiltration tube to filter the components less than 10KDa, and obtained two components, 3-10KDa and less than 3KDa. After pre-incubating MDCK cells with these components for 30 minutes, they were infected with influenza virus PR8 strain for 6 hours.

[0202] The results of real-time fluorescence quantitative PCR showed that after adding 3-10KDa LYM3 components to MDCK cells, the content of viral M1 gene in the cells was not significantly different from that in the control group, while after adding LYM3 components less than 3KDa to MDCK cells, the content of viral M1 gene in the cells was significantly reduced ( Fig.14 A), which indicates that the LYM3 component smaller than 3 kDa has antiviral function.

[0203] At the same time, after high temperature treatment, the component smaller than 3KDa lost its antiviral function. The same results were obtained in the immunoblotting experiment. After adding the component smaller than 3KDa, the NP / HA / M1 protein of the influenza virus PR8 strain was significantly reduced, and lost its antiviral ability after high temperature treatment ( Fig.14 B) These experimental results indicate that the antiviral functional components in the LYM3 supernatant are less than 3 KDa.

[0204] 4.4 Functional ingredients are not proteins

[0205] In order to determine whether the functional components in the supernatant of LYM3 bacteria less than 3KDa are proteins, 16 protein components were first purified using a protein purification and separation instrument. After pre-incubation of MDCK cells for 30 minutes, the influenza virus PR8 strain was infected for 6 hours. The results of real-time fluorescence quantitative PCR experiments showed that these 19 protein components had no antiviral function ( Fig.15 ).

[0206] Subsequently, a 0.22 μm PVDF membrane was used to filter the LYM3 supernatant with a size less than 3 KDa, and the proteins on the membrane were dissolved in PBS solution, ultimately obtaining two components: a flow-through without protein and proteins with a size less than 3 KDa. These two components were pre-incubated with MDCK cells for 30 min and then infected with influenza virus PR8 strain for 6 h.

[0207] The results of real-time fluorescence quantitative PCR experiments showed that the flow-through without protein still significantly reduced the content of viral M1 gene in cells, while proteins less than 3KDa did not affect the content of M1 gene in cells ( Fig.16 A), which indicates that the protein-free flow-through significantly inhibited the infection of influenza virus PR8 strain, while proteins smaller than 3 KDa had no antiviral function.

[0208] The same results were obtained by western blotting: after adding protein-free flow-through to MDCK cells, the NP / HA / M1 proteins of influenza virus PR8 strain were significantly reduced, while after adding proteins less than 3KDa, the viral proteins did not change significantly ( Fig.16 B) These results indicate that the antiviral functional component in the LYM3 supernatant is not a protein.

[0209] 4.5 Ethyl acetate extraction products have antiviral function

[0210] According to previous experiments, the functional component in the supernatant of LYM3 is not a protein, but is likely a small molecule. We used two organic solvents, ether and ethyl acetate, to extract the active components in the supernatant of LYM3. The extract was dried using a vacuum centrifugal concentrator and then redissolved. The extract was pre-incubated with MDCK cells for 30 minutes and then infected with influenza virus PR8 strain for 6 hours.

[0211] The results of real-time fluorescence quantitative PCR showed that compared with the blank control, both the ether and ethyl acetate extracts had antiviral functions, and the ethyl acetate component had a stronger function and was widely used for extraction ( Fig.17 ), so in the following experiments, ethyl acetate was used to extract the active components in the supernatant of LYM3.

[0212] 4.6M9-LYM3 supernatant has antiviral function

[0213] The medium used for LYM3 supernatant is BHI bacterial medium, which is rich in nutrients and complex in composition, is conducive to bacterial growth, but is not conducive to high-performance liquid chromatography analysis (HPLC). M9 medium is a bacterial medium prepared from several inorganic salts and glucose, with simple and known ingredients. After pre-incubation of MDCK cells with M9-LYM3 supernatant (LYM3 supernatant cultured in M9 medium) for 30 minutes, influenza virus PR8 strain was infected for 6 hours.

[0214] The results of real-time fluorescence quantitative PCR experiments showed that after adding M9-LYM3 supernatant to MDCK cells, the content of viral M1 gene in the cells was significantly reduced, which indicates that LYM3 supernatant cultured in M9 medium still has significant antiviral function ( Fig.18 ).

[0215] 4.7M9-LYM3 ethyl acetate extraction product has antiviral function

[0216] The M9-LYM3 supernatant was extracted with ethyl acetate in a ratio of 1:1, and the organic phase was washed twice with water. The active ingredient was then dried using a rotary evaporator and reconstituted with DMSO: water in a ratio of 1:1. We wanted to test at which dilution the reconstituted active ingredient still had significant antiviral function, which would be beneficial for the subsequent HPLC separation experiment. After pre-incubating MDCK cells with different dilutions of the M9-LYM3 supernatant for 30 minutes, the influenza virus PR8 strain was infected for 6 hours.

[0217] The results of real-time fluorescence quantitative PCR experiments showed that when 10-fold diluted M9-LYM3 ethyl acetate extract was added to MDCK cells, the content of viral M1 gene in the cells was significantly reduced, indicating that the M9-LYM3 ethyl acetate extract had significant antiviral function at a 10-fold dilution. As the dilution of the M9-LYM3 ethyl acetate extract increased, the antiviral function gradually declined, while the control group DMSO had no antiviral function even at a 10-fold dilution ( Fig.19 ).

[0218] 4.8 HPLC separation of antiviral functional components

[0219] According to previous experimental results, the ethyl acetate extract of M9-LYM3 still has a very significant antiviral function after being diluted 10 times. At this dilution factor, 2μl was taken for HPLC separation experiments, using Agilent ultra-high performance liquid chromatography, C18 column, flow rate 1mL / min, and each HPLC separation cycle was 30min. First, 3 groups of components were collected in groups of 10 minutes each. After drying and re-dissolving these components, MDCK cells were pre-incubated for 30 minutes. After 30 minutes, the influenza virus PR8 strain was infected for 6 hours.

[0220] The results of real-time fluorescence quantitative PCR experiments showed that compared with the virus-only group, the content of the viral M1 gene in the 11-20min group was significantly reduced ( Fig. 20 A), which indicates that the key functional components in the ethyl acetate extraction product of M9-LYM3 are eluted within 11-20 min.

[0221] Subsequently, within 11-20 minutes, 10 groups of components were collected, each 1 minute as a group, and these components were dried and re-dissolved, and then pre-incubated with MDCK cells for 30 minutes. After 30 minutes, the influenza virus PR8 strain was infected for 6 hours. The results of the real-time fluorescence quantitative PCR experiment showed that compared with the only virus group, the content of the viral M1 gene in the 14-minute group was significantly reduced ( Fig. 20 B), which indicates that the key functional components in the ethyl acetate extraction product of M9-LYM3 are eluted within the 14th minute.

[0222] 4.9 LC-MS / MS results analysis

[0223] The dried M9-LYM3 ethyl acetate extract was reconstituted with methanol for LC-MS / MS analysis. An Agilent ultra-high performance liquid chromatograph, Q Exactive plus (Orbitrap), C18 column, HPLC conditions were water / acetonitrile (10-100%), 0.1% formic acid, flow rate 1 mL / min. DDA analysis was performed in both forward and reverse modes (TOP5).

[0224] After comparing all conditions, the peak at 13.2 min was the most obvious peak observed in both positive and negative modes, indicating that the key functional component eluted at 13.2 min, which is consistent with previous experimental results ( Fig.21 At the same time, the mass spectrometry results showed that the molecular weight of the active ingredient may be 422Da ( Fig.21 ). If sulfur and phosphorus are not considered, the molecular formula of the compound may be C 21 H 25 N7O3 or C 20 H 29 N3O7.

[0225] 4.10The active ingredients in the supernatant of LYM3 inhibit the infection of other influenza virus subtypes.

[0226] MDCK cells were pre-incubated with the active component (BSD20) in the LYM3 supernatant for 30 min and then infected with influenza viruses G2H3N2, HK H3N2, California H1N1, H9N2, and H4N2 for 6 h.

[0227] The results of real-time fluorescence quantitative PCR experiments showed that the active ingredient (BSD20) in the supernatant of LYM3 significantly inhibited the proliferation of influenza virus G2 H3N2 ( Fig. 22 A), HK H3N2( Fig. 22 B) California H1N1 ( Fig. 22 C) H9N2 Fig. 22 D) H4N2( Fig. 22E) infection, and as the concentration of the active ingredient (BSD20) in the LYM3 supernatant increased, its antiviral function became stronger.

[0228] Strain preservation

[0229] The strain Bacillus zhangzhouensis LYM3 of the present invention has been deposited in the China Center for Type Culture Collection (CCTCC) on May 29, 2023, at No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province, China, with the deposit number: CCTCCM2023870. The viability of the strain was tested on June 5, 2023, and the result was survival.

[0230] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A Bacillus, It is characterized in that The deposit number of the bacillus is CCTCC M2023870.

2. A composition, It is characterized in that The composition comprises: (a) a safe and effective amount of the bacillus and / or its metabolite according to claim 1; and (b) a pharmaceutically acceptable carrier or a food acceptable carrier.

3. Use of the bacillus according to claim 1 or the composition according to claim 2, It is characterized in that Used for preparing medicines for preventing and / or treating viral infections.

4. A use of the bacillus according to claim 1 or the composition according to claim 2, It is characterized in that Used for preparing medicines or preparations, wherein the medicines or preparations are used for preventing and / or treating viral infections.

5. A method for preparing the composition according to claim 2, It is characterized in that Includes steps: The bacillus and / or its metabolite according to claim 1 is mixed with a pharmaceutically acceptable carrier or a food acceptable carrier to form the composition according to claim 2.

6. A production method, It is characterized in that Includes steps: (a) culturing the bacillus according to claim 1 under conditions suitable for cultivation, thereby obtaining a culture product; (b) optionally, isolating Bacillus cells and / or metabolites thereof from the culture product; and (c) Optionally, the Bacillus cells and / or their metabolites separated in the previous step are mixed with a pharmaceutically acceptable carrier or a food acceptable carrier to prepare a composition.

7. A method for inhibiting viruses in vitro, It is characterized in that Administer a safe and effective amount of the bacillus according to claim 1.

8. A method for inhibiting viruses in vivo, It is characterized in that A safe and effective amount of the bacillus according to claim 1 or the composition according to claim 2 is administered to the subject.

9. The method according to claim 8, It is characterized in that Said administration includes oral administration.

10. The method according to claim 8, It is characterized in that The dosage is 1×10-1×10 per person per day. 20 cfu / mL or cfu / g of the Bacillus as claimed in claim 1, preferably 1×10 4 -1×10 15 cfu / mL or cfu / g of the Bacillus.